BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 8652559)

  • 1. Photoreactivity of platinum(II) in cisplatin-modified DNA affords specific cross-links to HMG domain proteins.
    Kane SA; Lippard SJ
    Biochemistry; 1996 Feb; 35(7):2180-8. PubMed ID: 8652559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins.
    Ohndorf UM; Rould MA; He Q; Pabo CO; Lippard SJ
    Nature; 1999 Jun; 399(6737):708-12. PubMed ID: 10385126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laser-induced photo-cross-linking of cisplatin-modified DNA to HMG-domain proteins.
    Mikata Y; He Q; Lippard SJ
    Biochemistry; 2001 Jun; 40(25):7533-41. PubMed ID: 11412107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA sequence context and protein composition modulate HMG-domain protein recognition of cisplatin-modified DNA.
    Dunham SU; Lippard SJ
    Biochemistry; 1997 Sep; 36(38):11428-36. PubMed ID: 9298962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of Ixr1, a yeast HMG-domain protein, to cisplatin-DNA adducts in vitro and in vivo.
    McA'Nulty MM; Whitehead JP; Lippard SJ
    Biochemistry; 1996 May; 35(19):6089-99. PubMed ID: 8634251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities.
    Trimmer EE; Zamble DB; Lippard SJ; Essigmann JM
    Biochemistry; 1998 Jan; 37(1):352-62. PubMed ID: 9425057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single HMG domain in high-mobility group 1 protein binds to DNAs as small as 20 base pairs containing the major cisplatin adduct.
    Chow CS; Barnes CM; Lippard SJ
    Biochemistry; 1995 Mar; 34(9):2956-64. PubMed ID: 7893709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA sequence context modulates the impact of a cisplatin 1,2-d(GpG) intrastrand cross-link on the conformational and thermodynamic properties of duplex DNA.
    Pilch DS; Dunham SU; Jamieson ER; Lippard SJ; Breslauer KJ
    J Mol Biol; 2000 Feb; 296(3):803-12. PubMed ID: 10677282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction between cisplatin-modified DNA and the HMG boxes of HMG 1: DNase I footprinting and circular dichroism.
    Locker D; Decoville M; Maurizot JC; Bianchi ME; Leng M
    J Mol Biol; 1995 Feb; 246(2):243-7. PubMed ID: 7869375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recognition of DNA interstrand cross-link of antitumor cisplatin by HMGB1 protein.
    Kasparkova J; Delalande O; Stros M; Elizondo-Riojas MA; Vojtiskova M; Kozelka J; Brabec V
    Biochemistry; 2003 Feb; 42(5):1234-44. PubMed ID: 12564926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts.
    Vaisman A; Lim SE; Patrick SM; Copeland WC; Hinkle DC; Turchi JJ; Chaney SG
    Biochemistry; 1999 Aug; 38(34):11026-39. PubMed ID: 10460158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NMR solution structure of a DNA dodecamer duplex containing a cis-diammineplatinum(II) d(GpG) intrastrand cross-link, the major adduct of the anticancer drug cisplatin.
    Gelasco A; Lippard SJ
    Biochemistry; 1998 Jun; 37(26):9230-9. PubMed ID: 9649303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA oligonucleotide duplexes containing intramolecular platinated cross-links: energetics, hydration, sequence, and ionic effects.
    Kankia BI; Soto AM; Burns N; Shikiya R; Tung CS; Marky LA
    Biopolymers; 2002 Nov; 65(3):218-27. PubMed ID: 12228927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding of tsHMG, a mouse testis-specific HMG-domain protein, to cisplatin-DNA adducts.
    Ohndorf UM; Whitehead JP; Raju NL; Lippard SJ
    Biochemistry; 1997 Dec; 36(48):14807-15. PubMed ID: 9398202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA interactions of new cytotoxic tetrafunctional dinuclear platinum complex trans,trans-[{PtCl2(NH3)}2(piperazine)].
    Brabec V; Christofis P; Slámová M; Kostrhunová H; Nováková O; Najajreh Y; Gibson D; Kaspárková J
    Biochem Pharmacol; 2007 Jun; 73(12):1887-900. PubMed ID: 17400194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin.
    Takahara PM; Rosenzweig AC; Frederick CA; Lippard SJ
    Nature; 1995 Oct; 377(6550):649-52. PubMed ID: 7566180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nature of full-length HMGB1 binding to cisplatin-modified DNA.
    Jung Y; Lippard SJ
    Biochemistry; 2003 Mar; 42(9):2664-71. PubMed ID: 12614161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HMG-domain protein recognition of cisplatin 1,2-intrastrand d(GpG) cross-links in purine-rich sequence contexts.
    Cohen SM; Mikata Y; He Q; Lippard SJ
    Biochemistry; 2000 Sep; 39(38):11771-6. PubMed ID: 10995245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Site-specific d(GpG) intrastrand cross-links formed by dinuclear platinum complexes. Bending and NMR studies.
    Kaspárková J; Mellish KJ; Qu Y; Brabec V; Farrell N
    Biochemistry; 1996 Dec; 35(51):16705-13. PubMed ID: 8988007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single d(GpG)/cis-diammineplatinum(II) adduct-induced inhibition of DNA polymerization.
    Suo Z; Lippard SJ; Johnson KA
    Biochemistry; 1999 Jan; 38(2):715-26. PubMed ID: 9888812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.